Cost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice
Citation
Schackman, Bruce R, David W Haas, Sanghee S Park, X Cynthia Li, and Kenneth A Freedberg. 2016. “Cost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.” Pharmacogenomics 16 (18): 2007-2018. doi:10.2217/pgs.15.142. http://dx.doi.org/10.2217/pgs.15.142.Abstract
Aims To assess the cost–effectiveness of CYP2B6 genotyping to guide efavirenz dosing for initial HIV therapy in the USA. Methods: We used the Cost–Effectiveness of Preventing AIDS Complications (CEPAC) microsimulation model to project quality-adjusted life expectancy and lifetime costs (2014 US dollars) for efavirenz-based HIV therapy with or without CYP2B6 genotyping. We assumed that with genotyping 60% of patients would be eligible to receive lower doses. Results: Current care without CYP2B6 genotyping has an incremental cost–effectiveness ratio >$100,000/QALY compared with genotype-guided dosing, even if lower dosing reduces efficacy. When we assumed generic efavirenz availability, conclusions were similar unless lower dosing reduces efficacy by 6% or more. Conclusion: CYP2B6 genotyping can inform efavirenz dosing and decrease HIV therapy cost.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832977/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860273
Collections
- HMS Scholarly Articles [17917]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)